Poisblaud Lise, Kröger Edeltraut, Jauvin Nathalie, Pelletier-Jacob Julie, Bélanger Richard E, Foldes-Busque Guillaume, Aubin Michèle, Pluye Pierre, Guillaumie Laurence, Amiri Malek, Dagenais Pierre, Dionne Clermont E
Centre d'excellence sur le vieillissement de Québec (CEVQ), Centre Intégré Universitaire de Santé et de Services Sociaux de la Capitale-Nationale (CIUSSSCN), Québec, Quebec, Canada.
Centre de Recherche du CHU de Québec, Université Laval, Québec, Quebec, Canada.
J Pain Res. 2023 Oct 18;16:3463-3475. doi: 10.2147/JPR.S413450. eCollection 2023.
Explore perceptions and preoccupations regarding use of medical cannabis against chronic musculoskeletal pain, among patients and physicians.
Qualitative study using interviews with patients and physicians, based on the Theory of Planned Behavior (TPB).
The study was conducted in Quebec, Canada, in spring 2020.
We included 27 adult patients and 11 physicians (GPs, anesthesiologists, psychiatrists, and a rheumatologist); the mean age of patients was 48.2 years; 59.3% of patients and 36.4% of physicians were women; 59.3% of patients used no medical cannabis at the time of study; 45.5% of physicians had never authorized it.
Semi-structured interviews were conducted, transcribed and for the qualitative analysis codes were developed in a hybrid, inductive and deductive approach. Guided by the TPB, facilitators and barriers, perceived benefits and harms, and perceived norms that may influence cannabis use or authorization were documented.
Although medical cannabis is an interesting avenue for the relief of chronic musculoskeletal pain, doctors and patients agreed that it remained a last line option, due to the lack of scientific evidence regarding its safety and efficacy. The norms surrounding medical cannabis also play an important role in the social and professional acceptance of this therapeutic option.
Medical cannabis is seen as a last line option among interventions in the management of chronic pain, and attitudes and prior experiences play a role in the decision to use it. Study results may contribute to improved shared decision making between patients and physicians regarding this option.
探讨患者和医生对使用医用大麻治疗慢性肌肉骨骼疼痛的看法和关注点。
基于计划行为理论(TPB),采用对患者和医生进行访谈的定性研究。
该研究于2020年春季在加拿大魁北克进行。
我们纳入了27名成年患者和11名医生(全科医生、麻醉师、精神科医生和一名风湿病学家);患者的平均年龄为48.2岁;59.3%的患者和36.4%的医生为女性;59.3%的患者在研究时未使用医用大麻;45.5%的医生从未开具过医用大麻的处方。
进行半结构化访谈,转录访谈内容,并采用归纳与演绎相结合的混合方法制定定性分析代码。以TPB为指导,记录可能影响大麻使用或开具处方的促进因素和障碍、感知到的益处和危害以及感知规范。
尽管医用大麻是缓解慢性肌肉骨骼疼痛的一个有吸引力的途径,但医生和患者一致认为,由于缺乏关于其安全性和有效性的科学证据,它仍然是最后的选择。围绕医用大麻的规范在社会和专业层面接受这种治疗选择方面也发挥着重要作用。
医用大麻在慢性疼痛管理干预措施中被视为最后的选择,态度和既往经历在使用它的决策中起作用。研究结果可能有助于改善患者和医生之间关于这一选择的共同决策。